Exelixis has announced it has received FDA approval for Cabometyx to treat patients with hepatocellular carcinoma who previously underwent treatment with Nexavar, according to a press release.

“This new indication for Cabometyx is an important treatment advance for patients with this aggressive form of liver cancer, a community in need of new therapeutic options,” Michael M. Morrissey, PhD, president and CEO of Exelixis, said in the release. “This approval is an important milestone as we continue to explore how Cabometyx may benefit people with difficult-to-treat-cancers beyond renal cell carcinoma.”

Approval was based on results from the CELESTIAL phase 3 trial of Cabometyx (cabozantinib) for patients with HCC who previously received Nexavar (sorafenib, Bayer).

Continue reading

Share This Page

Follow Us